Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (33)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Pater, J. L.
Right arrow Articles by Chin, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pater, J. L.
Right arrow Articles by Chin, C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 8:181-185, 1997
© 1997 European Society for Medical Oncology

research-article

The role of the 5-HT3 antagonists ondansetron and dolasetron in the control of delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy

J. L. Pater1,, W. S. Lofters2, B. Zee1, E. Dempsey3, D. Walde4, J.-P. Moquin5, K. Wilson6, P. Hoskins7, R. M. Guevin8, S. Verma9, R. Navari10, J. E. Krook11, J. Hainsworth12, M. Palmer1 and C. Chin3

1NCIC Clinical Trials Group, Queen's University Kingston, USA
2Kingston Regional Cancer Centre Kingston, USA
3Hoechst-Marion Roussel Canada Inc Montreal, USA
4Algoma Group Health Centre, Sault Ste Marie, USA
5Hospital du Sacre-Coeur Montreal, USA
6BCCA - Vancouver Island Cancer Centre Victoria, USA
7BCCA - Vancouver Cancer Centre Vancouver, USA
8Hospital Saint-Luc Montreal, USA
9ORCC-General Division Ottawa, Canada, USA
10Simon-Williamson Clinic Birmingham, AL, USA
11Duluth CCOP Duluth, MN, USA
12Sarah Cannon Cancer Centre, Nashville Nashville, TN, USA

Correspondence to: Joseph L. Pater, MD, MSc, FRCP(C) Director, NCIC Clinical Trials Group Queen's University 82–84 Barrie Street Kington, ON K7L 3N6 Canada

BACKGROUND:: 5-HT3 antagonists are effective in reducing the acute nausea and vomiting caused by cancer chemotherapy. However, it is not clear whether continuing these agents beyond twenty four hours is useful in controlling emesis on days two to seven after chemotherapy.

PATIENTS AND METHODS:: Four hundred seven patients receiving moderately emetogenic chemotherapy who had been given dexamethasone 8 mg i.v. and either ondansetron 32 mg i.v. or dolasetron 2.4 mg/kg i.v. were randomized to continue either an oral form of their 5-HT3 antagonist (ondansetron 8 mg b.i.d. or dolasetron 200 mg daily) plus dexamethasone 8 mg p.o. daily or dexamethasone alone for days two to seven. Endpoints assessed by self-report were: 1) complete control (no vomiting, no rescue medications, no missing data) of emesis; 2) nausea severity; and 3) quality-of-life as measured by the EORTC QLQ-C30.

RESULTS:: Continuation of 5-HT3 antagonists improved slightly, but not significantly, the complete control rate (47% vs. 41%; P = 0.24 one-sided) after chemotherapy. However, mean nausea severity was significantly (P = 0.015 one sided) reduced (by 3 mm on a 10 cm scale) on the combined arm. Minimal differences in quality of life were observed

CONCLUSION:: The benefit of continuing 5-HT3 antagonists beyond 24 hours is modest and the merits of routine use in these circumstances debatable.

chemotherapy, clinical trial, emesis, 5-HT3, antagonists


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
M. G. Kris, P. J. Hesketh, M. R. Somerfield, P. Feyer, R. Clark-Snow, J. M. Koeller, G. R. Morrow, L. W. Chinnery, M. J. Chesney, R. J. Gralla, et al.
American Society of Clinical Oncology Guideline for Antiemetics in Oncology: Update 2006
J. Clin. Oncol., June 20, 2006; 24(18): 2932 - 2947.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
O. Geling and H.-G. Eichler
Should 5-Hydroxytryptamine-3 Receptor Antagonists Be Administered Beyond 24 Hours After Chemotherapy to Prevent Delayed Emesis? Systematic Re-Evaluation of Clinical Evidence and Drug Cost Implications
J. Clin. Oncol., February 20, 2005; 23(6): 1289 - 1294.
[Abstract] [Full Text] [PDF]

Home page
 Journal of Pharmacy PracticeHome page
R. H. Rosen
Management of Chemotherapy-Induced Nausea and Vomiting
Journal of Pharmacy Practice, February 1, 2002; 15(1): 32 - 41.
[Abstract] [PDF]

Home page
 NEJMHome page
The Italian Group for Antiemetic Research
Dexamethasone Alone or in Combination with Ondansetron for the Prevention of Delayed Nausea and Vomiting Induced by Chemotherapy
N. Engl. J. Med., May 25, 2000; 342(21): 1554 - 1559.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. J. Gralla, D. Osoba, M. G. Kris, P. Kirkbride, P. J. Hesketh, L. W. Chinnery, R. Clark-Snow, D. P. Gill, S. Groshen, S. Grunberg, et al.
Recommendations for the Use of Antiemetics: Evidence-Based, Clinical Practice Guidelines
J. Clin. Oncol., September 1, 1999; 17(9): 2971 - 2971.
[Full Text] [PDF]

Home page
 JCOHome page
R. M. Navari and P. J. Hesketh
Use of Placebos in Delayed-Emesis Studies
J. Clin. Oncol., May 1, 1999; 17(5): 1644 - 1644.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.